ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes (CaDDM)

This study is currently recruiting participants.
Verified by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), July 2008

Sponsors and Collaborators: National Institutes of Health (NIH)
Tufts Medical Center
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00436475
  Purpose

The purpose of the randomized trial is to quantify the effect of vitamin D and calcium supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for type 2 diabetes.


Condition Intervention Phase
Glucose Intolerance
Type 2 Diabetes Mellitus
Metabolic Syndrome
Drug: Vitamin D3 2,000 IU orally once daily
Drug: Calcium Carbonate 400 mg orally twice daily
Drug: Vitamin D3-Placebo
Drug: Calcium-Placebo
Phase I
Phase II

MedlinePlus related topics:   Diabetes   

Drug Information available for:   Calcium gluconate    Vitamin D    Ergocalciferol    Calcium carbonate    Cholecalciferol    Dextrose   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Factorial Assignment, Efficacy Study
Official Title:   Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • Insulin sensitivity, Insulin secretion and Disposition Index [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • glucose tolerance (fasting, after OGTT), systemic inflammation, lipoprotein profile, blood pressure, body weight and body composition [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
  • Genetic studies on Vitamin D related genes and risk of type 2 diabetes and cardiometabolic outcomes [ Time Frame: 4 months ] [ Designated as safety issue: No ]
  • To collect and archive biological specimens (serum, plasma, DNA) so that they can be used for testing of new hypotheses either within the parent stud or through future ancillary studies. [ Time Frame: 0 and 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment:   112
Study Start Date:   September 2007
Estimated Study Completion Date:   July 2010
Estimated Primary Completion Date:   July 2010 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1
Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
Drug: Vitamin D3 2,000 IU orally once daily
Vitamin D3 2,000 IU orally once daily
Drug: Calcium Carbonate 400 mg orally twice daily
Calcium Carbonate 400 mg orally twice daily
2
Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
Drug: Vitamin D3 2,000 IU orally once daily
Vitamin D3 2,000 IU orally once daily
Drug: Calcium-Placebo
Calcium-Placebo
3
Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
Drug: Calcium Carbonate 400 mg orally twice daily
Calcium Carbonate 400 mg orally twice daily
Drug: Vitamin D3-Placebo
Vitamin D3-Placebo
4
Vitamin D3-Placebo plus Calcium-Placebo
Drug: Vitamin D3-Placebo
Vitamin D3-Placebo
Drug: Calcium-Placebo
Calcium-Placebo

Detailed Description:

There is animal and human observational evidence to suggest that vitamin D and calcium are important in modifying t2DM risk but there are critical gaps in our knowledge about the clinical magnitude of the association with t2DM and potential mechanisms in humans. We are conducting a randomized trial to quantify the effect of vitamin D and calcium supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for t2DM. We anticipate that the research proposed in this application is significant because it will provide the basis for defining feasible nutritional interventions that promotes prevention of t2DM. Based on the results of the proposed studies and future work in this area, vitamin D and calcium supplementation can assume an important role in the treatment of t2DM and in the prevention of the disease in the 41 million Americans who are at risk of developing t2DM.

  Eligibility
Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Ethnicity: all ethnic groups
  • Gender: men and women
  • Age

    1. Lower age limit: 40 years inclusive
    2. Upper age limit: NONE
  • BMI

    1. Lower BMI limit: 25 inclusive
    2. Upper BMI limit: 40 inclusive
  • Glucose Intolerance / Mild Diabetes defined as

    1. Fasting glucose ≥100 mg/dl OR
    2. 2-hr glucose after OGTT ≥140 mg/dl OR
    3. 5.8 ≤ Hemoglobin A1c ≤ 7

Major Exclusion Criteria:

  • Diabetes requiring pharmacotherapy
  • Smoking
  • Hyperparathyroidism
  • Hypercalcemia (Calcium > 10.5 mg/dl)
  • Kidney stone
  • Pregnancy
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00436475

Contacts
Contact: Marie Francia, MD     617-636-2834     caddm@tufts-nemc.org    
Contact: Anastassios Pittas, MD     617-636-2834     caddm@tufts-nemc.org    

Locations
United States, Massachusetts
Tufts-New England Medical Center     Recruiting
      Boston, Massachusetts, United States, 02111
      Contact: Marie Francia, MD     617-636-2834     caddm@tufts-nemc.org    
      Contact: Noah Lubowsky, MD     617-636-2834     caddm@tufts-nemc.org    
      Principal Investigator: Anastassios G Pittas, MD MS            
      Sub-Investigator: Bess Dawson-Hughes, MD            
      Sub-Investigator: Frank Hu, MD PhD            

Sponsors and Collaborators

Investigators
Principal Investigator:     Anastassios G Pittas, MD MS     Tufts Medical Center    
  More Information


Related Info  This link exits the ClinicalTrials.gov site
 

Publications:

Responsible Party:   Tufts-New England Medical Center ( Anastassios G. Pittas )
Study ID Numbers:   DK76092, DK76092
First Received:   February 16, 2007
Last Updated:   July 11, 2008
ClinicalTrials.gov Identifier:   NCT00436475
Health Authority:   United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Glucose intolerance  
Type 2 diabetes mellitus  
Metabolic syndrome  

Study placed in the following topic categories:
Cholecalciferol
Metabolic Diseases
Glucose Intolerance
Diabetes Mellitus
Ergocalciferols
Endocrine System Diseases
Calcium Carbonate
Hyperglycemia
Vitamin D
Diabetes Mellitus, Type 2
Endocrinopathy
Glucose Metabolism Disorders
Metabolic disorder

Additional relevant MeSH terms:
Pathologic Processes
Disease
Molecular Mechanisms of Pharmacological Action
Growth Substances
Vitamins
Syndrome
Physiological Effects of Drugs
Bone Density Conservation Agents
Antacids
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers